IL6 and laryngotracheoesophageal cleft: Treatment of LC with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence has been reported [106,235,236,237,238,239,240].